Data on Kappaproct for Ulcerative Colitis to be Presented at 2016 United European Gastroenterology Week

Data on Kappaproct for Ulcerative Colitis to be Presented at 2016 United European Gastroenterology Week
InDex Pharmaceuticals will present additional data from its trial that investigated Kappaproct (cobitolimod) for treatment of moderate to severe active ulcerative colitis (UC). The data will be presented by Raja Atreya, a professor at the University of Erlangen-Nürnberg, during United European Gastroenterology Week (UEGW), Oct. 15-19, in Vienna. COLLECT (NCT01493960) was a placebo-controlled, double-blind, randomized study

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Craig Joinette says:

    This is good news for those of us that don’t want our immune systems beat down by the drugs they have now. Most, if not all reduce our immune systems ability to protect us from opportunistic diseases. I have refused biologic drug treatment because of this. I hope this is available soon, as I think the steroids are not working well for me anymore.

Leave a Comment

Your email address will not be published. Required fields are marked *